AAA Pharmaceutical, Inc. is recalling approximately 65,808 bottles of Ranitidine 150 mg tablets (the generic version of Zantac) because the active ingredient contains an impurity known as N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen, and its presence in the medication was discovered during testing. The recall includes 34,272 bottles of 24-count tablets and 31,536 bottles of 130-count tablets sold at various retail locations. If you are taking this medication, you should consult with your doctor or pharmacist to discuss alternative treatments.
NDMA is an environmental contaminant that is classified as a probable human carcinogen. While NDMA can be found in water and foods, chronic exposure to higher-than-acceptable levels in medications may increase the risk of cancer over time.
Full refund upon return of product.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.